Regulatory Policy


An ASGCT strategic objective is to promote a regulatory environment that supports clinical translation of gene and cell therapies. The unique attributes of these therapies and the rapid expansion of the pipeline in recent years pose challenges to both regulators and developers.

The Society advocates for predictable, efficient regulatory requirements to facilitate development of safe and effective therapies to alleviate human disease. Some examples of the policies ASGCT supports are as follows:

  • Robust federal appropriations to the US Food and Drug Administration (FDA).
  • Additional allocation of user fee dollars to FDA’s Center for Biologics Evaluation and Research (CBER).
  • Updated post-market surveillance expectations.
  • Use of surrogate endpoints when a strong mechanistic rationale exists.
  • Convergence of regulatory requirements across regulatory bodies globally.

Committee Involvement

The Regulatory Affairs Committee provides oversight of ASGCT’s efforts on regulatory policy through various activities, including an annual liaison meeting with the FDA to promote dialogue on the most pressing regulatory matters in the field. The committee also provides Society representation to entities developing gene and cell therapy standards. The Regulatory Affairs and Commercialization Committees develop programming for the Annual Meeting and annual Policy Summit on these topics.

Collaborative Efforts

ASGCT is a member of the following organizations:

The Society also has representation in the following groups:

Regulatory Lessons Learned From COVID-19: Anomaly to Precedent

This summary highlights valuable insights from regulatory leaders at FDA and EMA, among other speakers, from the Annual Meeting session, Regulatory Lessons Learned From COVID-19: Anomaly to Precedent.

2021

ASGCT Policy Summit

September 22-24, 2021

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.